These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 27143334)
1. Vilanterol trifenatate for the treatment of COPD. Malerba M; Radaeli A; Montuschi P; Morjaria JB Expert Rev Respir Med; 2016 Jul; 10(7):719-31. PubMed ID: 27143334 [TBL] [Abstract][Full Text] [Related]
2. Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma. Chang V; Gray EL; Thomas PS Expert Rev Respir Med; 2016 Oct; 10(10):1069-78. PubMed ID: 27599692 [TBL] [Abstract][Full Text] [Related]
3. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Blair HA; Deeks ED Drugs; 2015 Jan; 75(1):61-74. PubMed ID: 25398674 [TBL] [Abstract][Full Text] [Related]
4. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Feldman GJ; Edin A Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659 [TBL] [Abstract][Full Text] [Related]
5. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Bollmeier SG; Prosser TR Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654 [TBL] [Abstract][Full Text] [Related]
6. Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease. Parri G; Nieri D; Roggi MA; Vagaggini B; Celi A; Paggiaro P Expert Rev Respir Med; 2018 Dec; 12(12):997-1005. PubMed ID: 30463451 [No Abstract] [Full Text] [Related]
7. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Cazzola M; Segreti A; Matera MG Drug Des Devel Ther; 2013; 7():1201-8. PubMed ID: 24143077 [TBL] [Abstract][Full Text] [Related]
8. Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines. Davidson JF; Donohue JF; Ohar JA Expert Opin Drug Saf; 2015 Feb; 14(2):317-24. PubMed ID: 25598422 [TBL] [Abstract][Full Text] [Related]
9. Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. Ramadan WH; Al Masri S; Rizk J Clin Respir J; 2019 Nov; 13(11):663-673. PubMed ID: 31389190 [TBL] [Abstract][Full Text] [Related]
10. Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Lal C; Strange C Expert Opin Pharmacother; 2019 Jun; 20(9):1075-1085. PubMed ID: 30983423 [TBL] [Abstract][Full Text] [Related]
11. Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Caramori G; Ruggeri P; Casolari P; Chung KF; Girbino G; Adcock IM Expert Rev Respir Med; 2017 Dec; 11(12):955-967. PubMed ID: 28956463 [TBL] [Abstract][Full Text] [Related]
12. Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD. Caramori G; Chung KF; Adcock IM Int J Chron Obstruct Pulmon Dis; 2014; 9():249-56. PubMed ID: 24596460 [TBL] [Abstract][Full Text] [Related]
13. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease. Kelly E Expert Rev Clin Pharmacol; 2014 Jul; 7(4):403-13. PubMed ID: 24909949 [TBL] [Abstract][Full Text] [Related]
14. Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy. Albertson TE; Bullick SW; Schivo M; Sutter ME Drug Des Devel Ther; 2016; 10():4047-4060. PubMed ID: 28008228 [TBL] [Abstract][Full Text] [Related]
15. Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction. Antohe I; Antoniu SA; Gavrilovici C Expert Opin Pharmacother; 2018 Feb; 19(3):287-289. PubMed ID: 29271268 [TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD. Rodrigo GJ; Neffen H Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635 [TBL] [Abstract][Full Text] [Related]
18. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028 [TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872 [TBL] [Abstract][Full Text] [Related]
20. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]